A Brief Review of Thrombolytics for Venous Interventions

Abstract

Anticoagulation continues to be the mainstay of therapy for the management of venous thromboembolism. However, anticoagulation does not lead to the breakdown or dissolving of the thrombus. In an acute pulmonary embolism, extensive thrombus burden can be associated with a high risk for early decompensation, and in acute deep venous thrombosis, it can be associated with an increased risk for phlegmasia. In addition, residual thrombosis can be associated with chronic thromboembolic pulmonary hypertension and postthrombotic syndrome in a chronic setting. Thrombolytic therapy is a crucial therapeutic choice in treating venous thromboembolism for thrombus resolution. Historically, it was administered systemically and was associated with high bleeding rates, particularly major bleeding, including intracranial bleeding. In the last two decades, there has been a significant increase in catheter-based therapies with and without ultrasound, where lower doses of thrombolytic agents are utilized, potentially reducing the risk for major bleeding events and improving the odds of reducing the thrombus burden. In this article, we provide an overview of several thrombolytic therapies, including delivery methods, doses, and outcomes.

Keywords

thrombolysis - alteplase - venous thromboembolic disease - venous thromboembolism - interventional radiology

^* S.K.G. and A.L.H. are co–first authors.

Publikationsverlauf

Artikel online veröffentlicht:
17. November 2022

• References

• 1 Ortel TL, Neumann I, Ageno W. et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv 2020; 4 (19) 4693-4738
• 2 Huang W, Goldberg RJ, Anderson FA, Kiefe CI, Spencer FA. Secular trends in occurrence of acute venous thromboembolism: the Worcester VTE study (1985-2009). Am J Med 2014; 127 (09) 829-39 .e5
• 3 Kahn SR, Shrier I, Julian JA. et al. Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. Ann Intern Med 2008; 149 (10) 698-707
• 4 Vedantham S, Goldhaber SZ, Julian JA. et al; ATTRACT Trial Investigators. Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis. N Engl J Med 2017; 377 (23) 2240-2252
• 5 Martin C, Sobolewski K, Bridgeman P, Boutsikaris D. Systemic thrombolysis for pulmonary embolism: a review. P&T 2016; 41 (12) 770-775
• 6 Bivard A, Lin L, Parsonsb MW. Review of stroke thrombolytics. J Stroke 2013; 15 (02) 90-98
• 7 Dotter CT, Rösch J, Seaman AJ. Selective clot lysis with low-dose streptokinase. Radiology 1974; 111 (01) 31-37
• 8 Brayfield A. Martindale: The Complete Drug Reference. 40th ed. Pharmaceutical Press; 2020
• 9 Ucar EY. Update on thrombolytic therapy in acute pulmonary thromboembolism. Eurasian J Med 2019; 51 (02) 186-190
• 10 Sikri N, Bardia A. A history of streptokinase use in acute myocardial infarction. Tex Heart Inst J 2007; 34 (03) 318-327
• 11 Mark DB, Hlatky MA, Califf RM. et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995; 332 (21) 1418-1424
• 12 Ouriel K. Urokinase and the US Food and Drug Administration. J Vasc Surg 1999; 30 (05) 957-958
• 13 Collen D, Lijnen HR. The tissue-type plasminogen activator story. Arterioscler Thromb Vasc Biol 2009; 29 (08) 1151-1155
• 14 Nordt TK, Bode C. Thrombolysis: newer thrombolytic agents and their role in clinical medicine. Heart 2003; 89 (11) 1358-1362
• 15 Walley T, Dundar Y, Hill R, Dickson R. Superiority and equivalence in thrombolytic drugs: an interpretation. QJM 2003; 96 (02) 155-160
• 16 Adivitiya, Khasa YP. The evolution of recombinant thrombolytics: current status and future directions. Bioengineered 2017; 8 (04) 331-358
• 17 Benedict CR, Refino CJ, Keyt BA. et al. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA. Circulation 1995; 92 (10) 3032-3040
• 18 Van De Werf F, Adgey J, Ardissino D. et al; Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 1999; 354 (9180): 716-722
• 19 Grunwald MR, Hofmann LV. Comparison of urokinase, alteplase, and reteplase for catheter-directed thrombolysis of deep venous thrombosis. J Vasc Interv Radiol 2004; 15 (04) 347-352
• 20 Vedantham S, Piazza G, Sista AK, Goldenberg NA. Guidance for the use of thrombolytic therapy for the treatment of venous thromboembolism. J Thromb Thrombolysis 2016; 41 (01) 68-80
• 21 Enden T, Haig Y, Kløw NE. et al; CaVenT Study Group. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. Lancet 2012; 379 (9810): 31-38
• 22 Semba CP, Bakal CW, Calis KA. et al; Advisory Panel on Catheter-Directed Thrombolytic Therapy. Alteplase as an alternative to urokinase. J Vasc Interv Radiol 2000; 11 (03) 279-287
• 23 Benenati J, Shlansky-Goldberg R, Meglin A, Seidl E. Consultants from the Reteplase and Abciximab for Peripheral Vascular Interventions Conference; Society for Cardiovascular and Interventional Radiology. Thrombolytic and antiplatelet therapy in peripheral vascular disease with use of reteplase and/or abciximab. The SCVIR Consultants' Conference; May 22, 2000; Orlando, FL. J Vasc Interv Radiol 2001; 12 (07) 795-805
• 24 Patel NH, Krishnamurthy VN, Kim S. et al; CIRSE and SIR Standards of Practice Committees. Quality improvement guidelines for percutaneous management of acute lower-extremity ischemia. J Vasc Interv Radiol 2013; 24 (01) 3-15
• 25 Razavi MK, Wong H, Kee ST, Sze DY, Semba CP, Dake MD. Initial clinical results of tenecteplase (TNK) in catheter-directed thrombolytic therapy. J Endovasc Ther 2002; 9 (05) 593-598
• 26 Vedantham S, Salter A, Lancia S, Lewis L, Thukral S, Kahn SR. Clinical outcomes of a pharmacomechanical catheter-directed venous thrombolysis strategy that included rheolytic thrombectomy in a multicenter randomized trial. J Vasc Interv Radiol 2021; 32 (09) 1296-1309 .e7
• 27 Kaufman C, Kinney T, Quencer K. Practice trends of fibrinogen monitoring in thrombolysis. J Clin Med 2018; 7 (05) 111